Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-218-5 | CAS number: 4724-48-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
None
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 80 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The key study is GLP compliant with an high quality (Klimisch score = 1)
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The NOAEL is 80 mg/kg/day, based on the diminution of the percentage of the number of male, but it was considered to be unlikely.
There is no effect on the others parameters observed.
According to the column 1 of REACh Annex IX, a two-generation toxicity study should be performed if the 28-day or 90-day study indicates adverse effects on reproductive organs or tissues. In the present case, in a screening reprotoxicity study available, no toxicologically relevant effects (in absence of parental toxicity) were observed to assume that the registered substance should be considered as reprotoxic regarding the fertility. Therefore it can be considered that there is no datagap concerning the fertility endpoint.
Short description of key information:
Based on the experimental conditions of this study:
The No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 12 mg/kg/day,
The No Observed Effect Level (NOEL) for reproductive performance (mating and fertility) was considered to be 80 mg/kg/day,
The NOAEL for toxic effects on progeny was considered to be 80 mg/kg/day.
Justification for selection of Effect on fertility via oral route:
Only one study available
Effects on developmental toxicity
Description of key information
Based on the experimental conditions of this study:
The No Observed Adverse Effect Level (NOAEL)for both maternal and embryo fetal development was considered to be 30 mg/kg/day.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 30 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The key study is GLP compliant with an high quality (Klimisch score = 1)
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In a GLP OECD 414 compliant study, Octylphosphonic acid was daily administered a suspension in corn oil at dose-levels of 10, 30 or 100 mg/kg/day, from Day 6 to Day 20 p.c., by oral route (gavage), to mated female Sprague‑Dawley rats.
At 100 mg/kg/day, non adverse excessive salivation and piloerection were observed. A significantly reduced mean body weight gain was recorded between Days 9 and 12 p.c., and between Days 18 and 21 p.c.. Macroscopic findings were observed on stomach and on kidneys, and net body weight change was decreased when compared with controls. Fetal skeletal variations and malformations were observed.
At 30 mg/kg/day, macroscopic findings were observed on kidneys, and non adverse fetal skeletal variations were noted.
At 10 mg/kg/day, there were no effects of the test item. At 100 mg/kg/day, in the context of maternal toxicity, the test item treatment was associated with fetal dysmorphogenic potential.
Discussion on Fetal skeletal variations
At 100 mg/kg/day, an increased number of litters with fetuses with unossified or incomplete ossification of various part of the skeleton was noted, when compared to controls and Historical Control Data.
From 30 mg/kg/day, there was a dose-related increase in unossified distal phalanx when compared with controls. This was considered to be non adverse test item treatment-related.
These developmental variations were considered to be non adverse test item treatment-related and associated to low thebody weight gain.
These findings appear not relevant in the case of human exposure during organogenesis, because the skeletal development at parturition in humans is much more advanced than in rodent species. In conclusion, these findings were not considered as true congenital skeletal malformations, because they were reversible and were therefore considered as variations without any functional consequences.
Discussion on Fetal skeletal malformations
When compared with controls and Historical Control Data, there were increased fetal and litter incidences of squeletal malformations at 100 mg/kg/day (cervical ribs and absent of thoracic vertebra), and from 30 mg/kg/day (absent ribs). These malformations were considered to be related to the test item treatment and of toxicological importance.
At 10 and 30 mg/kg/day and when compared with the control group, there were increased percentages of fetuses and litters with skeletal malformations. However, each individual malformation was not observed at the high dose-level. Therefore, a test item treatment relationship was considered unlikely or of non toxicological significance.
No clear evidence on a dose response relationship was highlighted.
Conclusion
In absence of maternal toxicity, no teratogenic effects were observed, additionally no clear dose response relationship for fetal skeletal malformations were identified in the study.
Therefore, on the basis of the results obtained in this study, the No Observed Adverse Effect Level (NOAEL) was considered to be 30 mg/kg/day for both maternal parameters and for embryo-fetal development and no classification is retained for the test item.
Justification for classification or non-classification
Based on the available data, octylphosphonic acid is neither classified for fertility nor for developmental toxicity according to the Regulation (EC) No 1272/2008 and the Directive 67/548/EEC.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.